Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00079612
Status:
COMPLETED
Last Update Posted:
2014-12-19
First Post:
2004-03-09
Brief Title:
Study of Nexavar Sorafenib BAY 43-9006 in Patients With Advanced Refractory Cancer
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to
Find out if BAY 43-9006 prevents the growth of tumors
For patients who have stable cancer status after 3 months of treatment if it is safer andor more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time
Find out how long the effect of BAY 43-9006 is on tumors To assess the safety of BAY 43-9006 sorafenib in the treatment of advanced refractory cancers
Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients
Find out if BAY 43-9006 prevents the growth of tumors
For patients who have stable cancer status after 3 months of treatment if it is safer andor more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time
Find out how long the effect of BAY 43-9006 is on tumors To assess the safety of BAY 43-9006 sorafenib in the treatment of advanced refractory cancers
Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None